Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172469 | 0.95 | HTR2C (0.34) | HTR2CUSP30PDE5AADRA1ATAS1R3 | |
| SCHEMBL16922997 | 0.94 | ALOX5AP (0.36) | HTR2CUSP30ALOX5APFEN1 | |
| SCHEMBL10035142 | 0.94 | ALOX5AP (0.36) | HTR2CUSP30ALOX5APFEN1 | |
| SCHEMBL12994249 | 0.93 | HTR2C (0.41) | HTR2CUSP30PDE5AADRA1AALOX5AP | |
| SCHEMBL18808073 | 0.91 | USP30 (0.36) | HTR2CUSP30PDE5ATAS1R3TAS1R1 | |
| SCHEMBL803458 | 0.90 | ALOX5AP (0.34) | USP30ALOX5APFEN1 | |
| SCHEMBL13868125 | 0.90 | ALOX5AP (0.34) | USP30ALOX5APFEN1 | |
| SCHEMBL12999898 | 0.90 | ALOX5AP (0.41) | ALOX5APFEN1 | |
| SCHEMBL18435813 | 0.87 | HTR2C (0.33) | HTR2CUSP30PDE5AALOX5APFEN1 | |
| SCHEMBL20850068 | 0.87 | HTR2C (0.35) | HTR2CUSP30ADRA1ATAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024133363-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240067879-A1 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| WO-2024017812-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2024-01-25 | — | — | WO | disclosed |
| EP-4306615-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2024-01-17 | — | — | EP | disclosed |
| US-11873438-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| EP-4279565-A2 | THIOPHENE COMPOUND, LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | Merck Patent GmbH (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-20230357637-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357637-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| EP-4273207-A1 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3679111-B1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME | MERCK PATENT GMBH (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-20090309066-A1 | Mixture of polar compounds containing cyclohexane and benzene rings some of which are vinylene-linked, especially containing fluoroalkoxy groups; for electrooptical twisted nematic monitor applications | MERCK PATENT GESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2009129911-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH, (DE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009115186-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009033564-A2 | ELECTRO-OPTICAL LIGHT CONTROL ELEMENT, ELECTRO-OPTICAL DISPLAY AND CONTROL MEDIUM | MERCK PATENT GMBH (DE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090023802-A1 | Benzochromene Derivatives | MERCK PATENT GMBH (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080308768-A1 | Liquid Crystalline Medium | MERCK PATENT GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-7440160-B2 | Electro-optical light modulating element, electro-optical display and modulating medium | MERCK PATENT GMBH (DE) | 2008-10-21 | — | — | US | disclosed |
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080090026-A1 | Liquid-crystal display | MERCK PATENT GMBH | 2008-04-17 | — | — | US | disclosed |
| WO-2008009417-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177095-A1 | FUROCHROMAN DERIVATIVES | CFD, LMAN1, UROD | HTR2C 1360/4885USP30 4826/4885PDE5A 2975/4885 |
| US-20080090026-A1 | Liquid-crystal display | KLK3, LPXN, BPHL | HTR2C 1738/4885USP30 2486/4885PDE5A 366/4885 |
| US-20090023802-A1 | Benzochromene Derivatives | SBDS, CRY1, DDT | HTR2C 615/4885USP30 4733/4885PDE5A 2919/4885 |
| US-20090309066-A1 | Mixture of polar compounds containing cyclohexane and benzene rings some of which are vinylene-linked, especially containing fluoroalkoxy groups; for electrooptical twisted nematic monitor applications | VIM, CDH1, LEF1 | HTR2C 805/4885USP30 4856/4885PDE5A 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.